Cerevance Media Center
Current News
November 13, 2023
Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
September 19, 2023
Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease
Cerevance today announced that the first subject has been dosed in the Phase 1 clinical study evaluating the safety, tolerability, and pharmacokinetics of CVN293.
August 28, 2023
Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023
Cerevance has been named by Fierce Biotech as one of the most promising early-stage biotechnology companies in the industry in 2023, showcased on this year’s Fierce 15 list.
July 10, 2023
Cerevance to Present at the Alzheimers Association International Conference
Cerevance to present a poster presentation at the upcoming Alzheimer’s Association International Conference (AAIC), taking place in Amsterdam, Netherlands, July 16 – 20, 2023.
News Archive
September 23, 2024
Cerevance to Participate in a Panel Discussion at Fierce Biotech Summit 2024
Cerevance chief executive officer, Craig Thompson, will participate in a panel at the Fierce Biotech Summit, taking place in Boston, MA from September 30 – October 1, 2024.
June 18, 2024
Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024
Cerevance to deliver a poster presentation at the upcoming Federation of European Neuroscience Societies (FENS) Forum 2024, taking place in Vienna, Austria, from June 25 – 29, 2024.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disease caused by mutations in the ataxia-telangiectasia mutated gene, leading to progressive neurological issues. Using Cerevance’s NETSseq platform, RNA from purified cerebellar cell types of A-T and control donors was analyzed and subsequently revealed significant astrocyte gene expression changes related to inflammation and immune response.
March 20, 2023
AD/PD™ 2023 International Conference
March 7, 2023
Alzheimer’s Research UK Conference 2023
January 24, 2023
SVB Global Biopharma Conference
Events Archive
October 21, 2024
CVN424, a GPR6 inverse agonist, for Parkinson’s disease and motor fluctuations: a double-blind, randomized, phase 2 trial
April 5, 2024
Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment
February 26, 2024